CAR T-cell therapy targeting CD19 for patients with refractory lupus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 clinical trial evaluates the safety and efficacy of PiggyBac transposon-mediated Chimeric Antigen Receptor (CAR) T-cells that target CD19 in adults with refractory Systemic Lupus Erythematosus (SLE). Participants will undergo a conditioning chemotherapy regimen followed by the infusion of CAR T-cells derived from their own blood. The study aims to assess treatment-related toxicity, changes in SLE disease activity, and the persistence of the CAR T-cells in the body over time. This is a single-institution study conducted at King Chulalongkorn Memorial Hospital in Bangkok.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 and 60 years.
2. Diagnosis of Systemic Lupus Erythematosus (SLE), as defined by the American College of Rheumatology (ACR) 1997 criteria, The Systemic Lupus International Collaborating Clinics (SLICC) criteria, or the European Alliance of Associations for Rheumatology (EULAR)/ACR classification.
3. Refractory SLE, defined by one or more of the following:

   3.1 Persistently active SLE requiring ongoing maintenance therapy (if not contraindicated) with:
   * Antimalarial drug.
   * Either mycophenolate (minimum daily dose of 1500 mg) or azathioprine (minimum daily dose of 1.5 mg/kg).
   * Patients must also need a minimum daily dose of 7.5 mg prednisolone for lower disease activity maintenance, or have a SLEDAI score of 8 or higher.

   3.2 Biopsy-proven proliferative lupus nephritis after two standard induction therapies, including intravenous cyclophosphamide (cumulative dose of at least 1.5 g) and mycophenolate mofetil (administered for a minimum of 3 months), unless contraindicated.

   3.3 Worsening of biopsy-proven lupus nephritis (activity index \> 6 and chronicity index \< 6 within 6 months), indicated by increased proteinuria and/or decreased estimated glomerular filtration rate, despite treatment with high-dose corticosteroids (prednisolone at least 0.7 mg/kg/day or equivalent) and either mycophenolate mofetil or cyclophosphamide for a minimum of 14 days.
4. Ability to understand and willingness to sign a written informed consent document.
5. Participants of child-bearing or child-fathering potential must agree to practice birth control from enrollment until four months after receiving CAR T-cell infusion.

Exclusion Criteria:

1. Pregnant or breastfeeding women.
2. History of active malignancy, excluding non-melanoma skin cancer and carcinoma in situ (e.g., cervix, bladder, breast).
3. History of vital organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation.
4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, cirrhosis, or psychiatric illness/social situations that limit compliance with study requirements.
5. Any other clinically significant disease history or current disease that, in the judgment of the research physician, may pose a risk to the safety of the subjects or interfere with the research procedure, or the evaluation of safety and efficacy.
6. Serologic status indicating active HIV, hepatitis B, or C infection. Participants positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR prior to enrollment.
7. History of severe adverse drug reaction to Cyclophosphamide or Fludarabine.
8. Received a live vaccine within 30 days prior to CAR-T cell infusion.
9. eGFR CKD-EPI \< 30 ml/min/1.73m\^2.
10. Participation in other clinical investigations during the study period.
11. Prior receipt of CAR-T cell therapy outside this protocol.

Where it's running

• King Chulalongkorn Memorial Hospital
  Bangkok, Please Select, Thailand Recruiting

Study contacts

• Principal investigator: Wonngarm Kittanamongkolchai, MD — Chulalongkorn University
• Study coordinator: Wonngarm Kittanamongkolchai, MD
• Email: wonngarm.k@gmail.com
• Phone: 66875995974

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults

  This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07915102

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• CD19 CAR-T Therapy for Kids with Refractory Childhood SLE

  This study tests whether a patient’s own CD19 CAR-T cells can help children and young adults with severe, hard-to-treat lupus.

  Recruiting Phase 1 Seoul National University Hospital · Seoul · NCT07855302

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• CAR-T Cell Therapy for B-ALL (relapsed/refractory)

  This trial tests a patient’s own CAR-T cells to treat relapsed or refractory B-cell ALL in people aged 5–50.

  Recruiting Early Phase 1 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi · NCT07695012

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.